Why the study?
With the increasing prevalence of metabolic diseases and recent progress in surgical treatments, a comprehensive reference was needed on the pathogenesis, surgical approaches, and surgical outcome evaluation for cardiometabolic syndrome.
Surgical treatments, including metabolic and cardiovascular procedures, offer significant benefits for managing cardiometabolic syndrome, particularly in patients with obesity and type 2 diabetes.
Cardiometabolic syndrome (CMS) is a major risk factor for cardiovascular disease (CVD). It leads to increased cardiovascular and all-cause mortality. CMS is defined by the presence of abdominal obesity, hypertension, elevated triglycerides, reduced high-density lipoprotein cholesterol (HDL-C) levels, and glucose intolerance. With the increasing prevalence of metabolic diseases such as obesity and diabetes, CMS has become a significant threat to public health. As an intervention to improve the pathophysiological mechanisms of CMS, surgical treatment has achieved remarkable progress in recent years in the fields of metabolic surgery, cardiovascular reconstruction, and emerging technologies. Particularly for patients with obesity and type 2 diabetes accompanied by insulin resistance, surgical intervention can significantly improve metabolic parameters and cardiovascular outcomes. This article reviews the pathogenesis of CMS, surgical treatment approaches, and the evaluation of surgical outcomes, aiming to provide a comprehensive reference for the surgical management of CMS. By analyzing recent relevant studies, it discusses the current status and future directions of surgical treatment for CMS.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: